- Home
- KEY vs INCY Comparison
KEY vs INCY Comparison
Compare KEY & INCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KEY
- INCY
- Stock Information
- Founded
- KEY 1825
- INCY 1991
- Country
- KEY United States
- INCY United States
- Employees
- KEY N/A
- INCY N/A
- Industry
- KEY Major Banks
- INCY Biotechnology: Commercial Physical & Biological Resarch
- Sector
- KEY Finance
- INCY Health Care
- Exchange
- KEY Nasdaq
- INCY Nasdaq
- Market Cap
- KEY 20.8B
- INCY 17.0B
- IPO Year
- KEY N/A
- INCY 1993
- Fundamental
- Price
- KEY $17.30
- INCY $103.08
- Analyst Decision
- KEY Buy
- INCY Buy
- Analyst Count
- KEY 16
- INCY 19
- Target Price
- KEY $20.41
- INCY $89.19
- AVG Volume (30 Days)
- KEY 19.7M
- INCY 2.6M
- Earning Date
- KEY 10-16-2025
- INCY 10-28-2025
- Dividend Yield
- KEY 4.74%
- INCY N/A
- EPS Growth
- KEY 34785.88
- INCY 3878.02
- EPS
- KEY 0.86
- INCY 5.90
- Revenue
- KEY $5,934,000,000.00
- INCY $4,813,105,000.00
- Revenue This Year
- KEY $76.93
- INCY $19.33
- Revenue Next Year
- KEY $6.40
- INCY $10.47
- P/E Ratio
- KEY $20.02
- INCY $17.44
- Revenue Growth
- KEY 22.30
- INCY 18.09
- 52 Week Low
- KEY $12.73
- INCY $53.56
- 52 Week High
- KEY $20.04
- INCY $103.86
- Technical
- Relative Strength Index (RSI)
- KEY 40.90
- INCY 78.92
- Support Level
- KEY $17.30
- INCY $91.16
- Resistance Level
- KEY $17.81
- INCY $92.86
- Average True Range (ATR)
- KEY 0.38
- INCY 4.12
- MACD
- KEY 0.03
- INCY 1.30
- Stochastic Oscillator
- KEY 57.25
- INCY 96.07
About KEY KeyCorp
With assets of around $185 billion, Ohio-based KeyCorp's bank footprint spans 16 states, but it is predominantly concentrated in its two largest markets: Ohio and New York. KeyCorp is primarily focused on serving middle-market commercial clients through a hybrid community/corporate bank model.
About INCY Incyte Corp.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.